


ghp global
health
& pharma



Featuring:



Best Therapeutic Antibody Discovery Company 2023 - USA

OmniAb's mission is to enable the rapid development of innovative antibody therapeutics by providing its leading pharmaceutical and biotechnology partners with cutting-edge antibody discovery technologies. By combining the expansive and diverse antibody repertoires generated from OmniAb's groundbreaking four-species, in vivo discovery platform, with its cutting-edge, high-throughput screening tools and in silico capabilities, the company is delivering on its commitment of helping the industry discover the next-generation of therapeutic antibodies.

Q4 2023

Welcome to the Q4 2023 edition of Global Health & Pharma magazine, providing you with all of the latest news and features across the healthcare and pharmaceutical landscape.

As 2023 nears its end, it becomes a very fitting time to take a look back at the last 12 months and how the industry has continued to thrive. Medtech remains a very prominent concept, with organisations harnessing the power of cutting-edge technology to do incredible things.

For starters, on our front cover, we're pleased to feature the revolutionary OmniAb, our Best Therapeutic Antibody Discover Company 2023 – USA. Pushing the boundaries of therapeutic antibody discovery, OmniAb provides its pharmaceutical partners with the most diverse antibody repertoires and state-of-the-art screening technologies to facilitate the discovery of next-generation therapeutics.

Elsewhere, we're keen to promote how advancing tech has made rapid urine tests for HPV possible, an alternative method to cervical screening. A less invasive way of collecting cervical cell samples, this solution would be the ideal alternative for those who don't wish to attend cervical screenings, in turn, saving more lives.

From there, we showcase more of our award-winning firms who are also providing highly innovative solutions, whether food sensitivity and intolerance tests, prognostic diabetic biomarkers, PEMF therapy mats and devices, clinical skincare, luxury dental experiences, and many more. We also shine a light on outstanding organisations who are delivering crucial services in mental health treatment and eating disorder recovery care.

I hope you find this issue to be informative and insightful, the GHP team wishes you a wonderful end to 2023 and the most prosperous quarter ahead. In the meantime, we look forward to welcoming you back again in Q1 2024.

Rebecca Scotland, Editor
Website: www.ghp-news.com

All Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them.


The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions.

Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.



Contents

4. News
6. Best Therapeutic Antibody Discovery Company 2023 - USA
10. Best Independent Non- Commercial Dispensing Pharmacy 2023 – USA
12. Creating Healthy Healthcare Inventories
13. Award-winning Experts in Healthcare Communication
14. Urine tests for HPV, accessible screening for all could just be the key to preventing cervical cancer
15. Supplying the Means to Improve Life
16. Best Prognostic Diabetic Biomarker Development Company 2023 - Western Asia
17. NewMed Ltd: Your One- Stop-Shop for PEMF Therapy
18. Best Clinical Skincare Range 2023 (UK): SkinCycles
19. Best Cosmetic Injector 2023 (Central London): Alice Henshaw
20. Best Holistic Health Clinic 2023 - Sweden
21. An Innovative Leader in Polyclonal Antibody Development
22. Most Dedicated Domiciliary Care Service 2023 - East Midlands
23. A Customer-Centric Approach in the Pharmaceutical Industry
24. Get On Track!
25. Transforming Medicine Through Advanced AI
26. Most Compassionate Healthcare Network 2023 - Canada
28. Putting the 'You' in RejuvaYou
29. Elegantly Fusing Medicine and Beauty
30. Nurturing Communication Difference in Children
31. Extraordinary Expertise in the East Midlands
32. A Healthy Dose of Effective Communication!
33. A New Era of Dentistry
34. The Vital Need for Specialist Care to Help Adults Towards Eating Disorder Recovery
36. Advanced Skin Treatments for the Face and Body
37. Accelerators of Needed Change in Mental Health
38. Leading Innovation in the Dental Industry
39. Driving for State-of-the-Art Innovation in Life-Science
40. Best Specialist Oral Surgery Clinic 2023 - UK
42. Enhancing Natural Beauty
43. Best Spine Curvature Rehabilitation Centre 2023 - UAE
44. Most Innovative Mental Wellness Programming Provider 2023 - Midwest USA
45. Most Rejuvenating Aesthetics Clinic 2023 - Central London
46. Meet CHLOE
47. The UK's Leading Cosmetic Surgery Clinic
48. Healthcare-Focused Beverage Packaging Innovator of the Year 2023 - Switzerland
50. Best Psychological Live Events & Seminars Provider 2023 - Germany
51. Most Dedicated Cardiovascular Care Provider 2023 - New Jersey
52. For a More Natural Beauty
53. Medical Solutions for Events




An Innovative Leader in Polyclonal Antibody Development

Founded in 2008, SICGEN Antibodies has long been considered a leading enterprise on the European landscape, known for best-in-class development, manufacturing, and market penetration for polyclonal antibodies in cell biology research. Following the company's recognition in the Global Excellence Awards 2023 as Portugal's Antibody Development and Production Company of the Year, we spoke with Principal Researcher and Founder Jose Ramalho to find out more about the team's incredible work.

SICGEN Antibodies acts as a crucial accelerator in a space that, despite its constant forward momentum, can seem slow moving in comparison to sister industries that rely on its crucial work and research. Of course, it's a necessary aspect of the industry, as focused as it is on operating within a diligent, regulatory framework. In this, SICGEN Antibodies maintains a benchmark for development and deployment of polyclonal antibodies, setting the pace for others to follow in their footsteps.

But, let's go into more detail on some of the intricacies of the team's work. Jose offers more insight into the foundation of SICGEN Antibodies' expertise: "At a base level, the company develops, produces, and markets polyclonal antibodies that have been successfully used in several life sciences research areas. For example, the antibodies against fluorescent proteins such as GFP, mCherry, and tdTomato have featured in many life science research publications, such as Nature, Cell and Science."

As it stands currently, the company's product line has increased to some 300 products being used predominantly for research purposes. "With a particular focus on western blotting (WB), immunofluorescence (IF), and immunocytochemistry (IHC), although many are also utilized for ELISA, immunoprecipitation, and other biochemical techniques, SICGEN continuously strives to develop new antibody-related products and services for applications in industry and research," Joe adds. "Currently, SICGEN also produces custom polyclonal antibodies for leading national and international institutions, including universities, research institutes, pharmaceutical manufacturers and biotechnology distributors worldwide with its main market in North America, Europe, and Far East."



Putting aside its notable expertise and hard-earned tenure in the industry, Jose firmly believes that SICGEN Antibodies has succeeded through several variables, not least of which is the company's overall ability to meet demand and capitalize on opportunities as they arise. The team have been able to pivot towards meeting the supply of high-quality antibodies, utilizing the team's research and academic background to its advantage.

"As the company was developed from a scientific background, it has helped us to identify and focus our production on antibodies that we knew were in demand by the market. More than that, and perhaps more importantly, was our ability to anticipate how some scientific areas were likely to evolve and what would be their needs in terms of antibodies. By focusing on those products, we gained a competitive advantage and an opportunity in a very competitive market. We always try to take advantage of cutting-edge technologies on the area of antibody production."

"We are a resilient and hard working small team trying to be organized and focused on developing and producing a product of high standards. We are not afraid to study and learn from our competitors and provide a better product for your customers."

Over the last decade, the antibody landscape has changed dramatically on the back of scientific developments, however, there have and will always be notable challenges and obstacles to achieve enduring success. As we come to the close of our conversation with Jose, he spotlights some of the challenges SICGEN Antibodies has faced since its inception. "One of the key challenges has been in achieving manufacturing consistency and quality control. Addressing batch-to-batch variability through standardised manufacturing processes and robust quality control measures/ SICGEN Antibodies can enhance the reliability and reproducibility of antibodies. This can be achieved through stringent quality control testing, documentation, and process optimisation.

"Moreover, we have had to adapt to consistent technological advancements. The use of the latest technological advancements to develop antibodies with improved reproducibility and specificity can also provide new opportunities for innovation. By addressing these challenges and capitalising on opportunities, SICGEN Antibodies enhances the quality and reliability of our products, expands our market reach, and contributes to advancements in scientific research and discovery."

As for the future of the company, SICGEN Antibodies plans to continue on the path it has forged over the last 15 years, as Jose explains in his closing comments. "SICGEN Antibodies plans to continue developing, producing, and marketing some new antibodies in order to fill several antibody market gaps. In addition, we will try to reach new customers in different markets by increasing our distributor channels and implementing our free sample programme."

Company: SICGEN Antibodies
Email: jramalho@sicgen.pt
Web Address: www.sicgen.pt
Address: BIOCANT PARK Nucleo 04 Lt03, 3060-197
Cantanhede, Portugal
Telephone: +351 919145219

ghp global
health
& pharma

Subscribe to GHP

Subscribe here

www.ghp-news.com/subscribe

